Project Grant R44NS143486
Award Date 9/5/25
Completion Date 8/31/28
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Scottsdale, AZ 85258, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $459,097 Project Grant to Pison Technology, Inc., a minority-owned small business in Boston, Massachusetts. The grant, awarded on June 12, 2025, will fund the development of a digital biomarker for amyotrophic lateral sclerosis (ALS) using Pison's wrist-worn neural biosensor device. The goal is to leverage the...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding the development of a novel diagnostic assay for Parkinsonian tauopathies. The $446,991 award, made on Aug 7, 2025, supports the creation of aptamer-based ELISA assays to detect two tau peptides that can distinguish progressive supranuclear palsy (PSP) from corticobasal...
- This $616,200 Project Grant was awarded on February 1, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to explore the influence of neuromelanin, a dark pigment, on dopaminergic neurons in Parkinson's disease. The project aims to develop a novel mouse model that accumulates neuromelanin in dopamine neurons to study the resulting...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $679,899 to The University of Texas Southwestern Medical Center to explore the use of Positron Emission Tomography (PET) imaging to measure brain synaptic vesicle glycoprotein 2A (SV2A) as a potential biomarker for essential tremor, a common neurological condition affecting over 7...
- This Project Grant award of $395,951.00, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the commercial production of alpha-synuclein fibrils amplified from human postmortem brain tissue. The goal is to develop Lewy Fold Fibrils (LFFs), a new research tool that can overcome significant barriers to developing effective treatments for Parkinson's...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop a novel gene therapy approach to reduce neurotoxicity in Parkinson's disease. The $1,009,212 award to the Van Andel Research Institute in Grand Rapids, MI will fund pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to enhance the activity of the...
- This Project Grant award, totaling $684,451, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The primary objective is to develop an integrative machine learning pipeline to identify Parkinson's disease (PD) progression subtypes and potential drug targets through analysis of longitudinal clinical, transcriptomic, and neuroimaging data. Key...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify changes in synaptic vesicle-binding of alpha-synuclein as an early biomarker for Parkinson's disease (PD) and Alzheimer's disease related dementias (ADRD). The $793,535 award, with a project period from December 1, 2024 to November 30, 2029, will fund studies...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Brainstorm Therapeutics, Inc. aims to develop and validate a novel Parkinson's disease drug discovery platform using patient-derived midbrain organoids. The platform will guide therapeutic candidate identification, patient selection, and trial endpoint refinement to accelerate the development of effective disease-modifying Parkinson's treatments. Key innovations...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...